Reviewing Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX)

Profusa (NASDAQ:PFSA) and Perspective Therapeutics (NASDAQ:CATX) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares Profusa and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Perspective Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations for Profusa and Perspective Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Perspective Therapeutics	0	0	6	0	3.00

Perspective Therapeutics has a consensus price target of $11.17, indicating a potential upside of 134.10%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Perspective Therapeutics is more favorable than Profusa.

Insider and Institutional Ownership

9.8% of Profusa shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 11.4% of Profusa shares are owned by company insiders. Comparatively, 3.7% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Profusa has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

Earnings & Valuation

This table compares Profusa and Perspective Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$8.71 million	($2.23)	-1.35
Perspective Therapeutics	N/A	N/A	N/A	($0.90)	-5.30

Perspective Therapeutics is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Summary

Perspective Therapeutics beats Profusa on 7 of the 9 factors compared between the two stocks.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.